{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:30:39Z","timestamp":1794137439694,"version":"4.8.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003715","name":"KRIBB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020797","name":"NanoMedicines Innovation Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymthe.2025.03.060","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:04:33Z","timestamp":1743725073000},"page":"2565-2582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["The advent of clinical self-amplifying RNA vaccines"],"prefix":"10.1016","volume":"33","author":[{"given":"Irafasha C.","family":"Casmil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongwoo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jeong","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjoo","family":"Cha-Molstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5812-9689","authenticated-orcid":false,"given":"Anna K.","family":"Blakney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.060_bib1","unstructured":"Vaccines and immunization. https:\/\/www.who.int\/health-topics\/vaccines-and-immunization#tab=tab_1."},{"key":"10.1016\/j.ymthe.2025.03.060_bib2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S1473-3099(24)00158-0","article-title":"Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"24","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.060_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01722","article-title":"Vaccine Evolution and Its Application to Fight Modern Threats","volume":"10","author":"Andreano","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/d41573-023-00119-4","article-title":"The R&D landscape for infectious disease vaccines","volume":"22","author":"Yue","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.060_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bcp.12987","article-title":"Therapeutic nucleic acids: current clinical status","volume":"82","author":"Sridharan","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib6","article-title":"Engineering Gene Therapy: Advances and Barriers","volume":"4","author":"Shahryari","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coi.2016.05.008","article-title":"Recent innovations in mRNA vaccines","volume":"41","author":"Ulmer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib9","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2025.03.060_bib11","first-page":"403","article-title":"mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities","volume":"384","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.060_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib13","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.2922607","article-title":"Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells","volume":"243","author":"Xiong","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.060_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14760584.2.3.445","article-title":"Alphavirus vectors for vaccine production and gene therapy","volume":"2","author":"Lundstrom","year":"2003","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2025.03.060_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-55843-9","article-title":"Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers","volume":"16","author":"Maine","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.060_bib16","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-024-47905-1","article-title":"Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials","volume":"15","author":"Ho","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.060_bib17","article-title":"First self-amplifying mRNA vaccine approved","volume":"42","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib18","unstructured":"Agency., E.M. (2025). Kostaive https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kostaive."},{"key":"10.1016\/j.ymthe.2025.03.060_bib19","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","volume":"29","author":"Alwis","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.ymthe.2025.03.060_bib21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2217\/fmb.09.59","article-title":"A structural and functional perspective of alphavirus replication and assembly","volume":"4","author":"Jose","year":"2009","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008876","article-title":"A molecular understanding of alphavirus entry","volume":"16","author":"Holmes","year":"2020","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2025.03.060_bib23","doi-asserted-by":"crossref","first-page":"16534","DOI":"10.1073\/pnas.1210418109","article-title":"Structural and functional insights into alphavirus polyprotein processing and pathogenesis","volume":"109","author":"Shin","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.060_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0042-6822(89)90347-4","article-title":"The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83","volume":"170","author":"Kinney","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.060_bib25","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1128\/JVI.73.5.3854-3865.1999","article-title":"Selection of RNA Replicons Capable of Persistent Noncytopathic Replication in Mammalian Cells","volume":"73","author":"Frolov","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2017.01.007","article-title":"Alphavirus polymerase and RNA replication","volume":"234","author":"Pietil\u00e4","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib27","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.ymthe.2023.06.017","article-title":"A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation","volume":"31","author":"Kimura","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib29","article-title":"Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines","volume":"9","author":"Rijkers","year":"2021","journal-title":"Vaccines-Basel"},{"key":"10.1016\/j.ymthe.2025.03.060_bib30","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design","volume":"198","author":"Pepini","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2024.07.078","article-title":"Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity","volume":"374","author":"Bathula","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.03.060_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.omtn.2022.11.024","article-title":"Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines","volume":"31","author":"Tregoning","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.060_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161193","article-title":"Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge","volume":"11","author":"Magini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.060_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-59745-248-9_3","article-title":"Synthesis of RNA by In Vitro Transcription","volume":"703","author":"Beckert","year":"2011","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2025.03.060_bib35","first-page":"31","article-title":"Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action","volume":"440","author":"Maruggi","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.12688\/f1000research.75677.1","article-title":"Design-of-experiments in vitro transcription yield optimization of self-amplifying RNA","volume":"11","author":"Samnuan","year":"2022","journal-title":"F1000Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114247","article-title":"Effect of in vitro transcription conditions on yield of high quality messenger and self-amplifying RNA","volume":"198","author":"Popova","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ymthe.2025.03.060_bib38","first-page":"329","article-title":"A Method for Isolation of Intact, Translationally Active Ribonucleic Acid","volume":"2","author":"Cathala","year":"1983","journal-title":"DNA (Basel)."},{"key":"10.1016\/j.ymthe.2025.03.060_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.060_bib40","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.ymthe.2021.01.023","article-title":"Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs","volume":"29","author":"Zhong","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl. Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib42","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/nar\/gkt1321","article-title":"Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5\u2032-terminal regions of cap0-cap1- and 5\u2032ppp- mRNAs","volume":"42","author":"Kumar","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2015.01.019","article-title":"Innate immune restriction and antagonism of viral RNA lacking 2\u05f3-O methylation","volume":"479\u2013480","author":"Hyde","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.060_bib44","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1002\/cpz1.39","article-title":"Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap\u00ae Analog by In Vitro Transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.ymthe.2025.03.060_bib45","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1128\/JVI.00586-09","article-title":"Structural and Functional Elements of the Promoter Encoded by the 5\u2032 Untranslated Region of the Venezuelan Equine Encephalitis Virus Genome","volume":"83","author":"Kulasegaran-Shylini","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.virol.2009.02.027","article-title":"The 5'UTR-specific mutation in VEEV TC-83 genome has a strong effect on RNA replication and subgenomic RNA synthesis, but not on translation of the encoded proteins","volume":"387","author":"Kulasegaran-Shylini","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.060_bib47","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1128\/JVI.00599-15","article-title":"mRNA Capping by Venezuelan Equine Encephalitis Virus nsP1: Functional Characterization and Implications for Antiviral Research","volume":"89","author":"Li","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib48","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1128\/JVI.00553-15","article-title":"Noncapped Alphavirus Genomic RNAs and Their Role during Infection","volume":"89","author":"Sokoloski","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02342-18","article-title":"Increasing the Capping Efficiency of the Sindbis Virus nsP1 Protein Negatively Affects Viral Infection","volume":"9","author":"LaPointe","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ymthe.2025.03.060_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/acs.accounts.1c00621","article-title":"Machine Learning for Designing Next-Generation mRNA Therapeutics","volume":"55","author":"Castillo-Hair","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib51","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.apsb.2023.11.003","article-title":"A novel deep generative model for mRNA vaccine development: Designing 5\u2032 UTRs with N1-methyl-pseudouridine modification","volume":"14","author":"Tang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ymthe.2025.03.060_bib52","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3\u2032 UTRs Identified by Cellular Library Screening","volume":"27","author":"Niessen","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virusres.2015.01.016","article-title":"The 5' and 3' ends of alphavirus RNAs--Non-coding is not non-functional","volume":"206","author":"Hyde","year":"2015","journal-title":"Virus Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.virol.2013.07.021","article-title":"Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity","volume":"447","author":"Maruggi","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.060_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008825","article-title":"Cross-utilisation of template RNAs by alphavirus replicases","volume":"16","author":"Lello","year":"2020","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2025.03.060_bib56","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","article-title":"A critical analysis of codon optimization in human therapeutics","volume":"20","author":"Mauro","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib57","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.060_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab015","article-title":"Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses","volume":"3","author":"N\u00fa\u00f1ez-Manch\u00f3n","year":"2021","journal-title":"NAR Cancer"},{"key":"10.1016\/j.ymthe.2025.03.060_bib59","doi-asserted-by":"crossref","first-page":"10708","DOI":"10.1073\/pnas.1408677111","article-title":"Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs","volume":"111","author":"Kim","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.060_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01225-23","article-title":"Alphavirus-based replicons demonstrate different interactions with host cells and can be optimized to increase protein expression","volume":"97","author":"Dominguez","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202402936","article-title":"A Novel Self-Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations","volume":"11","author":"Gong","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2025.03.060_bib62","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10529-023-03379-7","article-title":"Mutations in the non-structural protein coding region regulate gene expression from replicon RNAs derived from Venezuelan equine encephalitis virus","volume":"45","author":"Lin","year":"2023","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ymthe.2025.03.060_bib63","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.1128\/JVI.79.12.7597-7608.2005","article-title":"Noncytopathic Replication of Venezuelan Equine Encephalitis Virus and Eastern Equine Encephalitis Virus Replicons in Mammalian Cells","volume":"79","author":"Petrakova","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib64","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1038\/s41598-019-43422-0","article-title":"In vitro evolution of enhanced RNA replicons for immunotherapy","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.060_bib65","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3390\/vaccines10091374","article-title":"A Bivalent Trans-Amplifying RNA Vaccine Candidate Induces Potent Chikungunya and Ross River Virus Specific Immune Responses","volume":"10","author":"Schmidt","year":"2022","journal-title":"Vaccines-Basel"},{"key":"10.1016\/j.ymthe.2025.03.060_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.omtm.2022.09.013","article-title":"Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets","volume":"27","author":"Chang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.060_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013924","article-title":"Double Subgenomic Alphaviruses Expressing Multiple Fluorescent Proteins Using a Rhopalosiphum padi Virus Internal Ribosome Entry Site Element","volume":"5","author":"Wiley","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2025.03.060_bib68","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.synbio.2021.09.003","article-title":"Synthetic polycistronic sequences in eukaryotes","volume":"6","author":"Wang","year":"2021","journal-title":"Synth. Syst. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib69","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ymthe.2020.11.011","article-title":"Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA","volume":"29","author":"Blakney","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib70","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/JVI.77.10.5598-5606.2003","article-title":"Sindbis Virus Vectors Designed To Express a Foreign Protein as a Cleavable Component of the Viral Structural Polyprotein","volume":"77","author":"Thomas","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib71","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/jvi.65.5.2501-2510.1991","article-title":"Analysis of Sindbis virus promoter recognition in vivo, using novel vectors with two subgenomic mRNA promoters","volume":"65","author":"Raju","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1566523023347742","article-title":"Polycistronic Viral Vectors","volume":"2","author":"Felipe","year":"2002","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib73","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.060_bib74","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.060_bib75","article-title":"An Update on Self-Amplifying mRNA Vaccine Development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.060_bib76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib77","article-title":"Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19","volume":"12","author":"Silva-Pilipich","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.060_bib78","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.ymthe.2024.06.031","article-title":"The tricky second album: Licensure of an mRNA vaccine for respiratory syncytial virus","volume":"32","author":"Tregoning","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.060_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103049","article-title":"Immune response to the components of lipid nanoparticles for ribonucleic acid therapeutics","volume":"85","author":"Chen","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib82","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.060_bib83","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jconrel.2021.12.008","article-title":"The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency","volume":"342","author":"Anderluzzi","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.03.060_bib84","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2025.03.060_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10600","article-title":"PEGylated therapeutics in the clinic","volume":"9","author":"Gao","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103505","article-title":"Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids","volume":"28","author":"Mendonca","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2025.03.060_bib87","article-title":"Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines","volume":"11","author":"Swetha","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.060_bib88","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2024.08.016","article-title":"The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA","volume":"374","author":"Barbieri","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.03.060_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102083","article-title":"mRNA vaccine trafficking and resulting protein expression after intramuscular administration","volume":"35","author":"Hassett","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.060_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114325","article-title":"In vivo fate and intracellular trafficking of vaccine delivery systems","volume":"186","author":"Lee","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2025.03.060_bib91","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acsinfecdis.9b00084","article-title":"Mannosylation of LNP Results in Improved Potency for Self-Amplifying RNA (SAM) Vaccines","volume":"5","author":"Goswami","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.060_bib92","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.omtn.2023.04.021","article-title":"Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2","volume":"32","author":"Lin","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.060_bib93","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.apsb.2023.10.012","article-title":"Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design","volume":"14","author":"Yan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ymthe.2025.03.060_bib94","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/08982104.2019.1652645","article-title":"Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review","volume":"30","author":"Pal Singh","year":"2020","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib95","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","article-title":"Strategies to reduce the risks of mRNA drug and vaccine toxicity","volume":"23","author":"Bitounis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.060_bib96","article-title":"Understanding Nanomaterial-Liver Interactions to Facilitate the Development of Safer Nanoapplications","volume":"34","author":"Li","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2025.03.060_bib97","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ebiom.2019.07.003","article-title":"Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia","volume":"45","author":"An","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2025.03.060_bib98","doi-asserted-by":"crossref","first-page":"28311","DOI":"10.1021\/acsnano.4c09677","article-title":"Amplification of Protein Expression by Self-Amplifying mRNA Delivered in Lipid Nanoparticles Containing a \u03b2-Aminoester Ionizable Lipid Correlates with Reduced Innate Immune Activation","volume":"18","author":"Lombaerde","year":"2024","journal-title":"Acs Nano"},{"key":"10.1016\/j.ymthe.2025.03.060_bib99","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib100","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4049\/immunohorizons.1900029","article-title":"Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties","volume":"3","author":"Besin","year":"2019","journal-title":"Immunohorizons"},{"key":"10.1016\/j.ymthe.2025.03.060_bib101","doi-asserted-by":"crossref","first-page":"e3672","DOI":"10.1002\/jgm.3672","article-title":"Trends in the synthetic polymer delivery of RNA","volume":"26","author":"Friesen","year":"2024","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib102","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-3659(03)00076-2","article-title":"Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine","volume":"89","author":"Kunath","year":"2003","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.03.060_bib103","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1039\/D3TB03003B","article-title":"Efficient in vitro and in vivo transfection of self-amplifying mRNA with linear poly(propylenimine) and poly(ethylenimine-propylenimine) random copolymers as non-viral carriers","volume":"12","author":"Opsomer","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ymthe.2025.03.060_bib104","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1021\/acs.biomac.0c00698","article-title":"The in Vitro, Ex Vivo, and in Vivo Effect of Polymer Hydrophobicity on Charge-Reversible Vectors for Self-Amplifying RNA","volume":"21","author":"Gurnani","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ymthe.2025.03.060_bib105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","article-title":"Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines","volume":"338","author":"Blakney","year":"2021","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.03.060_bib106","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqac004","article-title":"Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets","volume":"3","author":"McKay","year":"2022","journal-title":"Oxf. Open Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102159","article-title":"Polymeric nanoparticle-based mRNA vaccine is protective against influenza virus infection in ferrets","volume":"35","author":"Hardenberg","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.060_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213713","article-title":"A poly(amidoamine)-based polymeric nanoparticle platform for efficient in vivo delivery of mRNA","volume":"156","author":"Pontes","year":"2024","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.ymthe.2025.03.060_bib109","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/17425247.2021.1873272","article-title":"Application of chloroquine as an endosomal escape enhancing agent: new frontiers for an old drug","volume":"18","author":"Hajimolaali","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2025.03.060_bib110","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.omtn.2023.07.019","article-title":"Chloroquine and cytosolic galectins affect endosomal escape of antisense oligonucleotides after Stabilin-mediated endocytosis","volume":"33","author":"Pandey","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.060_bib111","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.060_bib112","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-00193-w","article-title":"An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model","volume":"7","author":"Chahal","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.060_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.colcom.2021.100533","article-title":"Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks","volume":"45","author":"Tayeb","year":"2021","journal-title":"Colloid Interf. Sci. Commun."},{"key":"10.1016\/j.ymthe.2025.03.060_bib114","article-title":"Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs","volume":"2023","author":"Preeti","year":"2023","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.ymthe.2025.03.060_bib115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.coviro.2020.08.003","article-title":"A new generation of vaccines based on alphavirus self-amplifying RNA","volume":"44","author":"Ballesteros-Briones","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib116","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion","volume":"211","author":"Bogers","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.060_bib117","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.03.060_bib118","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","article-title":"An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/ma15010179","article-title":"Polyethyleneimine-Based Lipopolyplexes as Carriers in Anticancer Gene Therapies","volume":"15","author":"Jerzykiewicz","year":"2021","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.060_bib120","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and Lipid Derivatives for RNA Delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ymthe.2025.03.060_bib121","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122682","article-title":"Recent Advances in Lipid Nanoparticles for Delivery of mRNA","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.03.060_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.060_bib124","doi-asserted-by":"crossref","first-page":"e2303370","DOI":"10.1002\/adma.202303370","article-title":"Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency","volume":"35","author":"Cheng","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2025.03.060_bib125","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1021\/acsami.4c20077","article-title":"Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels","volume":"17","author":"Liao","year":"2025","journal-title":"ACS Appl. Mater. Inter."},{"key":"10.1016\/j.ymthe.2025.03.060_bib126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","article-title":"A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine","volume":"7","author":"Low","year":"2022","journal-title":"npj Vaccin."},{"key":"10.1016\/j.ymthe.2025.03.060_bib127","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.060_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ymthe.2025.03.060_bib129","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.060_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.910136","article-title":"Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies","volume":"13","author":"Rice","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib131","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.060_bib132","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S1473-3099(24)00615-7","article-title":"12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.060_bib133","article-title":"Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study","volume":"4","author":"Akahata","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108964","article-title":"Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine","volume":"27","author":"Aboshi","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2025.03.060_bib135","article-title":"Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency","author":"McGee","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib136","doi-asserted-by":"crossref","DOI":"10.1093\/narmme\/ugae004","article-title":"Self-amplifying RNAs generated with the modified nucleotides 5-methylcytidine and 5-methyluridine mediate strong expression and immunogenicity in vivo","volume":"1","author":"Azizi","year":"2024","journal-title":"NAR Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib137","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib138","article-title":"Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review","volume":"10","author":"SeyedAlinaghi","year":"2022","journal-title":"Arch. Acad. Emerg. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib139","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.807","article-title":"Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia","volume":"11","author":"Yasmin","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.ymthe.2025.03.060_bib140","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1038\/s41467-023-39053-9","article-title":"GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for >\/=6 months in previously-vaccinated older adults","volume":"14","author":"Palmer","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.060_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101823","article-title":"COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2","volume":"56","author":"Szubert","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ymthe.2025.03.060_bib142","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"30","author":"Morse","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113900","article-title":"Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across","volume":"176","author":"Minnaert","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2025.03.060_bib144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drudis.2015.07.009","article-title":"Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger","volume":"21","author":"Devoldere","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2025.03.060_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114316","article-title":"Detection of Viral Infections by Innate Immunity","volume":"183","author":"Carty","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib146","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.cell.2024.03.036","article-title":"From periphery to center stage: 50 years of advancements in innate immunity","volume":"187","author":"Carpenter","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.060_bib147","first-page":"233","article-title":"The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses","volume":"316","author":"Sen","year":"2007","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib148","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib149","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","article-title":"Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.060_bib150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.060_bib151","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib152","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib153","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib154","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.omtm.2020.06.011","article-title":"Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection","volume":"18","author":"Erasmus","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.060_bib155","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Kariko","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011756","article-title":"Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins","volume":"5","author":"Angel","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.060_bib157","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3389\/fimmu.2016.00498","article-title":"Viral Evasion Strategies in Type I IFN Signaling - A Summary of Recent Developments","volume":"7","author":"Schulz","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib158","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1089\/hum.2017.121","article-title":"Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins","volume":"28","author":"Beissert","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114204","article-title":"Less is more: Self-amplifying mRNA becomes self-killing upon dose escalation in immune-competent retinal cells","volume":"196","author":"Vanluchene","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ymthe.2025.03.060_bib160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.stem.2013.06.001","article-title":"Efficient generation of human iPSCs by a synthetic self-replicative RNA","volume":"13","author":"Yoshioka","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2025.03.060_bib161","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2019.01.015","article-title":"New World alphavirus protein interactomes from a therapeutic perspective","volume":"163","author":"Carey","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib162","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41417-022-00435-8","article-title":"Next generation self-replicating RNA vectors for vaccines and immunotherapies","volume":"30","author":"Aliahmad","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib163","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ymthe.2024.12.055","article-title":"Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib164","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1128\/JVI.02073-06","article-title":"The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff","volume":"81","author":"Garmashova","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/v8060166","article-title":"Alphavirus Infection: Host Cell Shut-Off and Inhibition of Antiviral Responses","volume":"8","author":"Fros","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.060_bib166","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.virol.2015.04.023","article-title":"Control of alphavirus-based gene expression using engineered riboswitches","volume":"483","author":"Bell","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.060_bib167","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.3301","article-title":"Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery","volume":"33","author":"Wroblewska","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib168","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.201900247","article-title":"Synthetic mRNA-Based Systems in Mammalian Cells","volume":"4","author":"Ohno","year":"2020","journal-title":"Adv. Biosyst."},{"key":"10.1016\/j.ymthe.2025.03.060_bib169","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1021\/acssynbio.9b00343","article-title":"Orthogonal Protein-Responsive mRNA Switches for Mammalian Synthetic Biology","volume":"9","author":"Ono","year":"2020","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib170","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj1793","article-title":"A versatile and robust cell purification system with an RNA-only circuit composed of microRNA-responsive ON and OFF switches","volume":"8","author":"Fujita","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.03.060_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106335","article-title":"Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity","volume":"26","author":"Amano","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2025.03.060_bib172","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.ymthe.2020.11.010","article-title":"In Vivo Validation of a Reversible Small Molecule-Based Switch for Synthetic Self-Amplifying mRNA Regulation","volume":"29","author":"Cafferty","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib173","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41589-018-0146-9","article-title":"Small-molecule-based regulation of RNA-delivered circuits in mammalian cells","volume":"14","author":"Wagner","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib174","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11095-022-03166-5","article-title":"Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size","volume":"39","author":"Di","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2025.03.060_bib175","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1021\/acsnano.9b01444","article-title":"Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model","volume":"13","author":"Liu","year":"2019","journal-title":"Acs Nano"},{"key":"10.1016\/j.ymthe.2025.03.060_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101402","article-title":"Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites","volume":"33","author":"Parrett","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.060_bib177","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case","volume":"112","author":"Blenke","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ymthe.2025.03.060_bib178","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26926-0","article-title":"A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems","volume":"12","author":"Packer","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.060_bib179","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.11.022","article-title":"Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines","volume":"353","author":"Kim","year":"2023","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.03.060_bib180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41541-022-00549-y","article-title":"A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability","volume":"7","author":"Voigt","year":"2022","journal-title":"npj Vaccin."},{"key":"10.1016\/j.ymthe.2025.03.060_bib181","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.tibtech.2023.05.007","article-title":"Rise of the RNA machines - self-amplification in mRNA vaccine design","volume":"41","author":"Comes","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib182","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.ymthe.2024.07.003","article-title":"Can self-amplifying RNA vaccines and viruses exchange genetic material?","volume":"32","author":"Casmil","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib183","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/apb.2022.0037","article-title":"Viral Replicon Systems and Their Biosafety Aspects","volume":"28","author":"van der Meulen","year":"2023","journal-title":"Appl. Biosaf."},{"key":"10.1016\/j.ymthe.2025.03.060_bib184","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.ymthe.2024.06.019","article-title":"Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo","volume":"32","author":"Hick","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.060_bib185","article-title":"mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.060_bib186","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.060_bib187","article-title":"Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation","volume":"15","author":"Hangiu","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:05:36Z","timestamp":1759611936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":187,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525001625002692"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.060","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The advent of clinical self-amplifying RNA vaccines","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}